186 related articles for article (PubMed ID: 29732928)
1. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan.
Tanaka M; Matsumaru N; Tsukamoto K
Ther Innov Regul Sci; 2019 Mar; 53(2):199-206. PubMed ID: 29732928
[TBL] [Abstract][Full Text] [Related]
2. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
Tajima G; Matsumaru N; Tsukamoto K
J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
[TBL] [Abstract][Full Text] [Related]
3. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status.
Muensterman ET; Luo Y; Parker JM
Ther Innov Regul Sci; 2020 May; 54(3):658-666. PubMed ID: 33301147
[TBL] [Abstract][Full Text] [Related]
5. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
6. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
Daizadeh I
Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
[TBL] [Abstract][Full Text] [Related]
8. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
Maeda H; Kurokawa T
Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
[TBL] [Abstract][Full Text] [Related]
9. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
Monge AN; Sigelman DW; Temple RJ; Chahal HS
JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
[TBL] [Abstract][Full Text] [Related]
10. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Demirci E; Omes-Smit G; Zwiers A
Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
[TBL] [Abstract][Full Text] [Related]
11. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
12. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
13. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
14. Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.
Nakajima K; Chiba K; Tsubamoto H; Walsh J; Strawn L; Suwa T
Invest New Drugs; 2013 Aug; 31(4):1051-5. PubMed ID: 23250712
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
Pregelj L; Hine DC; Kesselheim AS; Darrow JJ
Clin Pharmacol Ther; 2021 Oct; 110(4):1018-1024. PubMed ID: 34048058
[TBL] [Abstract][Full Text] [Related]
16. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
Maeda H; Kurokawa T
J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
[TBL] [Abstract][Full Text] [Related]
17. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
18. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
19. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
Jeong H; Purja S; Kim E
Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status.
Muensterman ET; Luo Y; Parker JM
Ther Innov Regul Sci; 2019 Sep; ():2168479019874062. PubMed ID: 31558045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
